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DETECTION OF Toxoplasma gondii SOLUBLE ANTIGEN, SAG-1(p30), ANTIBODY AND IMMUNE
COMPLEX IN THE CEREBROSPINAL FLUID OF HIV POSITIVE OR NEGATIVE INDIVIDUALS

Flávia A. CHAVES-BORGES(1), Maria A. SOUZA(1), Deise A. O. SILVA(1), Lloyd H. KASPER(2) & José R. MINEO(1)

SUMMARY
Active infection by T. gondii was evaluated by immunoassay for soluble SAG-1 (p30), the major surface antigen from T. gondii,
specific antibodies and immune complexes in human cerebrospinal fluid (CSF) samples. A total of 263 samples of CSF were collected
from hospitalized patients presenting neurological disorders and analyzed for antibodies to HIV. Patients were divided into two
groups: HIV positive (n = 96) or HIV negative (n =167). The results of the assays showed that 45% of all samples were positive for
soluble SAG-1. Toxoplasma Ag/Ab immune complexes were detected in 19% of the CSF samples and 62% were positive for T.
gondii- specific IgG. A combination of these assays in the presence of clinical findings consistent with active Toxoplasma infection
may predict the presence of toxoplasmic encephalitis. Moreover, detection of soluble SAG-1 in the CSF of these individuals appears
consistent with active infection.
KEYWORDS: T. gondii; SAG-1 (p30) antigen; AIDS; Encephalitis; Human cerebrospinal fluid

INTRODUCTION
Toxoplasma gondii, an intracellular coccidian, infects a wide range
of eukaryotic cells and is an important opportunistic pathogen in humans
and animals. The infection is frequently encountered without any symptom
but there are two groups of high-risk individuals, the human fetuses and
the immunosuppressed persons, particularly those with acquired
immunodeficiency syndrome (AIDS), that frequently develop fatal
toxoplasmic encephalitis (TE)29. In these patients, the diagnosis relies on
a compatible clinical presentation, serologic evidence of exposure to T.
gondii, and the presence of cerebral lesions by imaging (either MRI or
CT). The diagnosis is confirmed if a response to specific treatment is
observed within 20 days, as determined by radioimaging scan. However,
there are limiting factors to this treatment strategy. For example, the level
of antibody may not be correlated with active infection and furthermore
unnecessary therapy can be dangerous because of the potential for bone
marrow toxicity with anti-T. gondii drugs. Therefore, accurate diagnosis
of toxoplasma infection is essential for improved prognosis.
Toxoplasma gondii has several molecular components that have been
evaluated as possible diagnostic tools. A group of proteins from 2638kDa can be detected, by Western blot, in cerebrospinal fluids and
serum of patients, during toxoplasmosis41. The major surface protein of
the parasite, SAG-1 (p30) is included among these proteins23. This protein
belongs to a group of excreted-secreted antigens (ESA)3,7,35 and is
involved in host immunity38. Polyclonal antibodies to p30 have been

identified in the serum of acute and chronically infected patients and in
congenitally infected individuals.
P30 antigen is stage-specific in that it is expressed exclusively by
tachyzoites that are the fast replicative form of the parasite. This molecule
is involved in parasite attachment14,31 and could represent an important
indicator of active infection since it can be a circulating antigen7,37.
Immunoenzymatic assays, ELISA (Enzyme-linked Immunosorbent
Assay), have been used in the diagnostics of toxoplasmosis 6,12,30.
Quantification of antigenemia has been studied by ELISA and
immunoblot method1,2,4,16.
The polymerase chain reaction (PCR) has been successfully applied
to detect Toxoplasma DNA or RNA in the cerebrospinal fluid of groups
of AIDS patients15,26. However, it has been recently demonstrated that
PCR, although diagnostics for primary infection, may be of a limited
value for diagnosis of toxoplasmic encephalitis in AIDS patients10.
Detection of parasite nucleic acid by PCR may be not correlated with
active infection since chronic infection may be associated with intervals
of parasitemia during asymptomatic phases of the disease9,24.
In the present study, we describe an ELISA system for simultaneous
detection of soluble SAG-1 (p30) antigen, IgG antibodies to T. gondii
and immune complex in human cerebrospinal fluid (CSF) samples in
those who are HIV seropositive.
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MATERIALS AND METHODS
Cerebrospinal fluid samples. This work was conducted in accordance
with the guidelines of the Ethical Committee at the General Hospital at
University of Uberlândia.
A total of 263 cerebrospinal fluid (CSF) samples were randomly
obtained at the Clinical Laboratory of the General Hospital of the Federal
University of Uberlândia, from July 1994 to April 1996. All samples
were kept at –20 °C until be tested.
After being tested for simultaneous detection of soluble SAG-1 (p30)
antigen, IgG antibodies to T. gondii and immune complex, the results of
these samples were retrospectively analyzed with the clinical data
presented at the files from those patients.
Production of anti-P30 monoclonal antibodies. BALB/c mice were
immunized i.p. with 1.5 x 107 tachyzoites of T. gondii RH strain
previously treated by acetone at 30% for 72 h at 4 °C, at days 0, 14, 28
and 42. At day 46, the spleen was removed and the spleen cells were
fused with SP2O/Ag 1417. The supernatants of hybridomas growing under
the HAT selection were screened for anti-T. gondii antibodies by an
indirect ELISA. The positive hybridomas were expanded and the cells
were cloned by limiting dilution, being further assessed by another
screening round. The positive clones were characterized by Western blot
against SDS T. gondii lysates, demonstrating reactivity to a band of 30
kDa (p30). Further characterization was carried out by isotyping of antip30 monoclonal antibodies using the Mouse Typer-Bio-Rad Kit
(Hercules, USA). 6A8 mAb to p30, which was obtained as described,
was used as a positive control31.
Excreted-secreted antigens (ESA) T. gondii RH strain tachyzoites
were harvested from mice peritoneal exsudates 2 days after the inoculation
of parasites. The suspension was selected when parasite containing ranged
from 107 to 108 parasites/ml, followed by centrifugation at 1000g for 15
min. The sediment was resuspended in 10 ml of sterile PBS at 4 °C and
centrifuged again at the same conditions as above described. The sediment
was resuspended in 0.5 ml of sterile PBS, and incubated at 37 °C for 45
min under eventual stirrings and centrifuged at 1000g for 15 min. The
supernatant was filtered in 0.2µm membrane (Sterile Acrodisc 13, Gelman
Sciences, USA) and was stored at –20 °C. The protein concentration of
the ESA was determined by using bovin serum albumin as standard28.
The electrophoretic profile of the ESA proteins was analyzed by SDSPAGE25 in 15% gel without reducing conditions and stained by silver
stain13. The p30 relative concentration in the ESA preparations was
estimated by densitometry in different samples of the metabolic antigen.
The determination was performed in a densitometer at 525 nm (Helena
J. France S.A., Saint-Leula, Forêt, France).
P30 antigen detection. Monoclonal anti-p30 antibodies (6A8 and
6E9) were coated onto wells of polyvinylchloride microtiter plates
(Falcon, Oxnard, USA) at concentration of 50 µg/ml. The volume added
was 50µl/well and the plates were incubated in a humid chamber, for
18 h at 4 °C. After this incubation, the plates were washed three times
for 5 minutes with PBS-T 0.05% (Sigma, St. Louis, USA). Following
washing, 50 µl/well of each CSF sample was added and incubated for
2 h at 37 °C. The negative controls consisted of CSF samples obtained
from patients negative for anti-HIV and for p30 antigen, anti-T. gondii
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antibodies and immune complex. ESA was added to samples with this
same profile in order to obtain positive controls. Plates were incubated
for 2 h at 37 °C, in a humid chamber and were washed again three
times. A volume of 50 µl/well of the biotinylated mouse IgG anti T.gondii was added after diluted 1/200 in PBS-T 0.05%. The reaction
was incubated for 45 min at 37 °C and then washed in the same
conditions described above. The avidin-biotin system (ABC-Vectastain
Kit, Vector Laboratories, Inc., Burlingame, CA, USA) was used
according to manufacturer instructions and, after incubation for 45
min and washes, the substrate solution was added. This consisted of a
solution of H2O2 and o-phenylenediamine (Merk, Schchardt, Germany)
in 0.1M citrate-Na2HPO4 buffer, pH 5.5. The reaction was stopped
after 15 min with 2N H2SO4. The reading was carried out at 492 nm in
a spectrophotometer microwell reader system (Organon Teknika,
Belgium) at 492 nm.
Anti-T. gondii IgG detection. Polyvinylchloride microplates were
coated with 50 µl of ESA antigen (5 µg/ml) for 18 h at 4 °C. The plates
were washed three times with phosphate-buffered saline 0.01M pH 7.2
containing 0.1% Tween-20 (PBS-T) and blocked during 30 min at room
temperature with 5% goat serum in PBS-T. After a new cycle of washes,
50 µl of undiluted CSF samples were added in duplicate and incubated
for 45 min at 37 °C. As controls, it was used negative and positive CSF
samples for IgG anti-T. gondii antibody, and controls for conjugate and
substrate, as well. Microplates were washed three times and 50 µl of
goat IgG anti-human IgG peroxidase (Sigma, St. Louis, USA), diluted
1/4000 in PBS-T, were added and incubated for 45 min at 37 °C. After
another series of washes, as described above, the plates were incubated
with substrate solution consisting of H2O2 and o-phenylenediamine in
0.1M citrate-Na2HPO4 buffer (pH 5.5) for 15 min at room temperature.
The reaction was stopped with 2N H2SO4 and the absorbance was
determined at microwell reader system (Organon Teknika, Belgium) at
492 nm.
Immune complex detection. Polyvinylchloride microplates were
coated for 18 h at 4 °C with 50 µl of IgG obtained from supernatants of
6A8 and 6E9 mAbs (50 µg/ml). After three washes with PBS-Tween 20
(0.05%), 50 µl/well of undiluted CSF samples were added and incubated
for 2 h at 37 °C. Positive and negative CSF samples to immune complex
were used as control. The positive CSF samples consisted of a positive
sample for anti -T. gondii IgG which was added of ESA and pre-incubated
for 1 h at 37 °C. After incubation for 45 min at 37 °C and a new cycle of
washes, it was added the conjugate goat IgG anti- human IgG-peroxidase.
After incubation for 45 min at 37 °C and another three washes, the
substrate solution was added (50 µl/well) and the reaction was stopped
as previously described.
ELISA sensitivity and specificity for P30 antigen detection. To
determine the sensitivity of the P30 ELISA, the CSF samples were
substituted by ESA solutions diluted in PBS-T 0.05%. The end point
was obtained with the maximum dilution in which the absorbance values
were higher than those obtained with the negative controls, determined
as cut off values. The sensitivity was calculated based in P30 concentrations, obtained by densitometry as above described. The specificity
of the P30 ELISA was determined by assessing 29 different antigenic
extracts of microorganisms widely spread in nature, obtained by
preparation of soluble extracts as generally used for intradermic cutaneous
tests (Alerbras and Alergofar, Rio de Janeiro, Brasil): Candidina,
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Table 1 shows the results of simultaneous detection of the markers P30
/Ab/IC among the test population. Among the 96 HIV seropositive group,
69 (72%) exhibited anti-T. gondii IgG whereas among the 167 anti-HIV
negative samples, 95 (57%) were positive. There were no significant
differences between the prevalence of anti-T. gondii IgG antibodies in the
HIV positive samples and HIV negative samples (p = 0.2349).

Escherichia coli, PPD, Tricofitina, Estreptoquinase/Estreptodornase,
Aspergillus sp., Alternaria sp., Cladosporium sp., Rhizopus sp.,
Penicillium sp., Rhodotorula sp., Diplococcus pneumoniae,
Streptococcus viridiam, Streptococcus dyogene, Streptococcus faecalis,
Neisseria catarrhalis, Staphylococcus sp., Aerobacter aeruginosa,
Proteus vulgaris, Salmonella group, Klebsiella pneumoniae, Shigella
group, Staphylococcus toxoids, Streptococcus toxoids, Haemophilus
influenzae, T. cruzi, Leishmania amazonensis, cetonic extract of Dengue
virus and soluble extract of Cysticercus cellulosae. All these preparations
had a protein concentration varying from 20 to 25 µg. ESA preparation
(19.5 µg) and PBS were used, as positive and negative controls,
respectively.

P30 was detected in 119 (45%) of the CSF samples. Among the
anti-HIV positive and negative samples, the positivity of p30 protein
was 54% and 40%, respectively, showing a statistically significant
difference between these two groups (p < 0.05) (Table 1).
Immune complex (IC) was detected in 50 samples (19%). Its
incidence was higher in samples of the group of the HIV positive patients
(29%) than in the samples of the HIV negative group (13%) (p = 0.0009)
(Table 1).

Indirect ELISA for anti-HIV IgG detection. The reactions for the
detection of anti-HIV IgG in the CSF samples were carried out using
anti-HTLV-III Kit (“Vironostika” Organon Boxtel,) following the
instructions of the manufacturer. The CSF samples were assayed
undiluted at one volume of 50 µl.

The analysis of the results showed that positive results for both IgG
anti-T. gondii and p30 antigen were found in 35% of the total CSF
samples. Positive results for anti-T. gondii and negative results for p30
antigen were found in 27%, whereas negative results for anti-T. gondii
and positive results for P30 were observed in 10% of the samples (p <
0.001) (Table 1).

Statistical analysis. The results of the studied tests were analyzed
by the “Statistic for Windows- Release 4.5 A” program (Statesoft, Inc.
1993). X 2, McNemar and Fisher’s exact tests were performed for
evaluation of the differences between two or more proportions. The null
hypothesis was rejected when p < .05.
RESULTS
Characterization of the assays. Samples of excreted-secreted
antigens were obtained (protein concentrations from .38 to 1.7 mg/ml)
and analyzed by SDS-PAGE. Following staining and densitometry, the
concentration of SAG-1 was determined and the sensitivity of the assay
was estimated at a minimum of 5 ng. Specificity was investigated against
unrelated antigens, with 29 samples comprising a group of pathogens
commonly found in nature. By taking the cut off as the medium value of
negative controls plus 3 standard-deviations, all these samples displayed
absorbances lower than the cut off, thus evidencing the specificity of the
test for detection of SAG-1 (p30).
Detection of soluble SAG-1(p30), antibody and immune complex in
CSF samples. Among the 263 CSF samples examined, 96 (37%) were
diagnosed as positive to HIV and 167 (63%) samples had negative results.
A total of 164 (62%) CSF samples were positive to anti-T. gondii IgG
and 99 (38%) were negative.

The incidence of IC was higher in positive IgG anti-T. gondii samples
(17%) than in negative samples (2%) ( X2 = 16.98; p = 0.0001) and
was higher in p30 positive samples (16%) compared to p30 negative
samples (3%) (X2 = 12.29; p< 0.001) .
Positive results for the three markers were found in 37 samples (14%)
and results entirely negative were found in 72 (27%) of the samples.
Positive samples for detection of p30 antigen or antibody were found in
21 (8%) and 65 (25%) of the studied samples, respectively.
Further comparison of these results was done based on the reactivity
for HIV infection. It was observed that the incidence of positive results
for all markers was higher in the HIV positive group (20%) than in the
HIV negative group (11%) (p < 0.05). Considering the detection of at
least one marker, represented by the SAG-1 (p30) antigen or immune
complex, as indicative of active infection, the HIV positive group also
showed higher incidence than the HIV negative group (p < 0.01). Figure
1 shows the correlation between the quantitative data for p30 and IC
assays, demonstrating a significant correlation index for both HIV

Table 1
Results of the detection of molecular markers P30/Ab/IC (p30 soluble antigen, IgG anti-T. gondii and immune complex) obtained by
immunoenzymatic assays in 263 cerebrospinal fluid samples that were positive or negative for IgG anti-HIV

Detection of P30 antigen, IgG antibody or Immune complex a
P30/Ab/IC

P30/Ab

P30/IC

P30

Ab/IC

Ab

No detection

Total

HIV+

19

23

4

6

5

22

17

96

HIV-

18

32

2

15

2

43

55

167

Total

37

55

6

21

7

65

72

263

a

(P30) = p30 antigen, major surface antigen of T. gondii; (Ab) = IgG antibody to T. gondii; (IC) = immune complex
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Fig. 1 - Correlation between the detection of P30 soluble antigen and immune complex (IC), obtained by immunoenzymatic assays in 263 cerebrospinal fluid samples from positive or negative
IgG anti-HIV patients.
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positive and HIV negative samples (p = 0.0128 and p = 0.0021,
respectively).
Association of clinical data with the results of the CSF markers. The
presence of active infection was defined when the P30 antigen and/or
Immune complex assays was/were positive in CSF samples. As
demonstrated in Table 2 and according to the clinical data presented in
the patient files, it was observed that the active infection was present in
all groups, in samples from both HIV positive and negative patients.

Detection of p30 /Ab/IC in CSF samples from children. Figure 2
shows the results of simultaneous detection of the studied markers among
17 CSF samples from children aged from newborn to 12-month old.
These samples were also tested for the presence of anti-HIV antibodies.
It was found that 65% of these samples were positive for p30 and, among
these, 36% were positive exclusively for this marker. The detection of
P30/Ab/IC showed no significant difference between the HIV positive
and HIV negative groups.

Table 2
Evidence of active T. gondii infection among HIV positive and HIV negative CSF samples according to the clinical data presented in
the patient files

Clinical Hypothesis

Evidence of active
infectiona

Anti-HIV antibodies
Positive
Negative

Cerebral toxoplasmosis
(acquired or congenital)

13/26 (50%)

9

4

Other CNS infectious diseases
(cysticercosis, syphylis,
cryptococcosis, meningococcal or
asseptic meningitis)

30/63 (48%)

13

17

Not infectious CNS diseases

44/103 (43%)

15

29

Not available clinical data

39/71 (55%)

20

19

Total

126/263 (48%)

57

69

a

ratio between the number of samples presenting active infection and the total number of samples. The presence of active
infection was defined when the P30 antigen and/or Immune complex assays was/were positive in CSF samples.

Number of samples (%)

40
35
30
25
20
15
10
5
0

P30/Ab/IC

P30/Ab

P30/IC

P30

Ab/IC

Ab

No
detection

Detection of P30 antigen, IgG antibody or Immune complex
Fig. 2 - Incidence of molecular markers P30/Ab/IC (P30 soluble antigen, IgG anti -T. gondii and immune complex) obtained by immunoenzymatic assays among 17 cerebrospinal fluid samples
from children under 1 year-old that were positive (white columns) or negative (black columns) for IgG anti-HIV.

333

CHAVES-BORGES, F.A.; SOUZA, M.A.; SILVA, D.A.O.; KASPER, L.H. & MINEO, J.R. - Detection of Toxoplasma gondii soluble antigen, SAG-1(p30), antibody and immune complex in
the cerebrospinal fluid of HIV positive or negative individuals. Rev. Inst. Med. trop. S. Paulo, 41(6): 329-338, 1999.

Table 3
Association of clinical signs obtained in the files of 17 patients aged from newborn to 12 month-old with the ELISA results to SAG-1 (p30) T. gondii antigen,
antibody, and immune-complex in cerebrospinal fluid samples

Detection of p30 antigen (P30), Antibody (Ab) and/or
Immune-complex (IC)
Sample

Age

Number

P30/Ab/IC
HIV
+

1

12m

2

11m

HIV
-

P30/Ab
HIV
+

HIV
-

P30/IC
HIV
+

HIV
-

P30
HIV
+

Clinical signs

HIV
+

in the patient files

HIV
-

x

Congenital toxoplasmosis

x

Cerebral paralysis

3

12m

4

3m

x
x

Hydrocephalus

5

3m

x

Hydrocephalus

6

NB

Hydrocephalus Myelomeningocele

7

1m

8

NB

x

Cerebral malformation, with areas of
encephalic absence
x

x

Malnutrition, anemia, dehydratation
Intracraniane hemorrhage, hydrocephalus

9

NB

10

NB

x

x
x

NA
Arm muscle tonus disturbs

11

2m

12

12m

x

Treated bacterial meningitis

13

12m

x

Hydrocephalus

14

12m

x

Convulsions

15

12m

16

1m

17

1m

m= month NB= newborn

NA

x

Cerebral cysts, meningitis
x
x

X= association between test results and clinical data

Association of clinical data with the results obtained in the CSF
samples from children. Table 3 shows that the results expressing active
infection accomplished 65% of the samples. Among ten patients
presenting at least one symptom related to the Sabin’s tetrad, 8 (80%)
of them presented CSF samples considered positive for active infection.
Five out of nine samples with clinical evidences of other diseases were
totally negative for p30, IgG antibody and immune complex. The
remaining four samples were positive for only the p30 antigen. In
addition, the presence of p30 and IC was occurred in 6/7 children with
clinical signs of hydrocephalus and generalized brain affection as
compared with 0/10 in other diseases. Even if the two cases without
clinical diagnosis will be excluded, it was observed a significant definition
of those tests in this group of patients (p = 0.0014).
Detection of p30 /Ab/IC in multiple CSF samples from AIDS patients.
Figure 3 shows the results of simultaneous detection of the markers
p30/Ab/IC in multiple samples from 3 patients who were HIV positive
and had clinical symptoms of toxoplasma encephalitis. It was observed
that the detection of p30 was positive in these individuals. Moreover,
there was a significant increase in reactivity of the CSF samples during
disease progression. In only one patient the p30 detection was
334

HIV
-

No detection

Marasmus, vomit
Congenital syphilis

NA= not available

accomplished by the detection of antibody against T. gondii and
increasing amounts of immune complex (Figure 3B).
DISCUSSION
The diagnosis of T. gondii infection in humans can be determined
by a variety of immunological molecular methods. The identification of
the parasite in blood and other organic fluids or in tissue can confirm the
etiology of the infection. Although presence of tissue cysts and free
tachyzoites in brain or in placenta is diagnostic, it is impractical. Current
parasitologic methods for the detection of parasites are at insufficient
sensitivity for accurate detection of infection in the newborn or
compromised host. Therefore, the methods dealing with anti-T. gondii
antibody or circulating antigen detection are more widely used. The
methodology for antibody detection is well established, allowing the
identification of serologic profiles, correlated with the stage of the
infection5,6. The presence of circulating antigen from the parasite in
infected human beings has been intensively investigated and consists in
an important indicator of active infection. So far, it has been described
that the detection of circulating antigen has limited value in the
immunocompromised individuals or newborns27.
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B
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C
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C
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C
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27-Apr-95

Date of sample collection

P30

Ab

IC

Fig. 3 - Detection of p30 soluble antigen (P30), IgG anti -T. gondii (Ab) and immune complex (IC) by immunoenzymatic assays in CSF samples from patients with Toxoplasma encephalitis.
(A) D.M.F., HIV-seropositive, 35 year-old, female; (B) N.P.S., HIV-seropositive, 48 year-old, male; (C) D.F.S., HIV-seropositive, 18 year-old, male.
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The present study characterizes the profile of the simultaneous
detection of p30 antigen of T. gondii, antibody and immune complex in
CSF samples of HIV seropositive and seronegative individuals. Among
263 CSF samples randomly collected, approximately one third came
from HIV positive patients. These data demonstrate the high index of
HIV patients among those searching for medical assistance, probably
because they do have developed neurological disorders, indicated by
the fulfillment of lumbar puncture to obtain CSF samples.

can be transported from the blood or from brain extracelullar fluid to the
CSF through the cuboid cells of plexus-coroide. Besides molecules that
are specifically transported, hydrophobic molecules can exceed the
barrier36. Perhaps, this fate explains the high incidence of P30 protein in
the CSF samples here examined. It was verified recently, by
immunohistochemical studies of the brain, that the incidence of infection
of the choroid plexus in AIDS patients with cerebral toxoplasmosis was
53% in a total of 17 cases11.

The high prevalence of anti-T. gondii antibodies (62%) among the
samples tested reflects the high degree of the infection in the region.
This prevalence did not differ between positive and negative HIV samples.
These results are consistent with studies that suggest toxoplasmic
encephalitis in AIDS is due to reactivation of latent infection than acquired
acute infection29. These results also suggest that the reactivation of the
infection may be correlated with p30 levels at CSF. Since p30 is a
stage-specific marker for the tachyzoites, it is indicator of active disease.
Considering the high prevalence of the T. gondii infection among the
HIV positive samples, it has to point out the importance of the knowledge
of the reactivity profile for toxoplasmosis since that positive results can
alert to future complications coming upon from AIDS.

Presence of immune complex, associated with the absence of
detectable levels of antibodies or free P30 can be an indicative of the
stage of immune response to the infection. Predominance of immune
complex in HIV positive samples may be associated with compromising
of the mononuclear phagocytic system responsible for IC clearance from
CSF. This could promote a longer persistence of the IC in this and other
organic fluids19,22.

The presence of p30 antigen among HIV positive (54%) and negative
(40%) samples was high, indicating that detection of p30 protein has
diagnostic value in both groups of patients. Thus, it appears that the rise
in p30 levels may be correlated with onset of active infection.
It was shown that p30 antigen was detected in 35% of the CSF
samples which also presented IgG anti-T. gondii antibodies. From the
total p30 positive CSF samples, 10% displayed negative results to antiT. gondii IgG. The absence of anti-T. gondii IgG antibodies in serum
and/or CSF samples in patients with toxoplasmosis has been reported in
the literature21. Circulating antigen of this parasite was detected in
serological negative samples in patients with toxoplasmosis 16 and
antigens of molecular weight of 4 kDa were identified33. The presence
of clinical symptoms suggestive of acquired infection as lymphadenopaty,
and negative serology can not exclude the toxoplasmosis diagnosis
because the humoral responses in some patients can be delayed creating
difficulty in the definitive diagnosis8,20.
Although intrathecal antibody production may establish a specific
indicator of toxoplasmic encephalitis, approximately 50% of the patients
will not present a detection of antibody in the CSF samples34,40. Important
differences related to the avidity of the IgG antibody can be detected
when it was compared paired samples of the CSF/serum and constitute
in a direct indicator of the IgG intrathecal production32. The presence of
anti-T. gondii IgG antibodies of low avidity in serum samples of patients
presenting recent primary infection was described in the literature18.
Evidence of compartimentalization of anti-T. gondii humoral immune
response was observed by the synthesis of IgG antibodies of low avidity
in aqueous humor samples of patients presenting toxoplasmic
retinochoroiditis39.
The blood-brain barrier may represent an obstacle to immunoglobulin
and mononuclear cells passage from the blood to the CSF. This data
perhaps can justify the non detection of anti-T. gondii IgG antibodies in
the CSF samples that presented the p30 antigen. However, this antigen
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Combined positive results for p30/Ab/IC were more frequent in HIV
positive samples. Among the 62% of samples with anti-T. gondii
antibodies, this marker was the only positive reaction in 25% of the total
samples, while p30 or IC were also positive in the remaining 37%. These
observations support the hypothesis that the search for the three markers
(p30/Ab/IC) might add a new piece of information in the pathogenesis
of human toxoplasmic encephalitis. Moreover, detection of p30 in 45%
of the studied CSF samples indicates a high incidence of active infection
in the group here included.
Taken into account the results of these three markers, the presence
of active infection was detected in CSF samples from patients presenting
various clinical data, but it should be pointed out that some of them the
first diagnostic hypothesis was not cerebral toxoplasmosis. This
emphasizes the clinical application of these assays, with the objective of
helping diagnosis and improving prognosis of those patients infected
with T. gondii.
RESUMO
Detecção de antígeno solúvel de Toxoplasma gondii SAG-1(p30),
anticorpo e imuno complexo em amostras de líquido
cefalorraqueano de pacientes HIV positivos ou negativos
Foi investigada a presença de infecção ativa pelo T. gondii em
pacientes hospitalizados apresentando acometimentos neurológicos
diversos. Amostras de líquido cefalorraquiano (LCR) foram analisadas
em imunoensaios padronizados para a detecção de três marcadores
moleculares: antígeno solúvel contendo epítopo imunodominante da
superfície parasitária SAG-1 (p30), anticorpos específicos e
imunocomplexos. Foram coletadas 263 amostras de LCR que foram
inicialmente analisadas quanto a presença de anticorpos anti-HIV. Os
pacientes foram divididos em dois grupos: HIV positivos (n = 96) ou
HIV negativos (n =167). Os resultados dos ensaios demonstraram que
45% do total de amostras foram positivas para o antígeno SAG-1 (p30).
Imunocomplexos foram detectados em 19% das amostras analisadas e
62% foram positivas para anticorpos IgG anti-T. gondii. A associação
destes resultados com os achados clínicos consistentes com a presença
de infecção ativa pelo Toxoplasma pode ser de importância no diagnóstico
da encefalite toxoplásmica.

CHAVES-BORGES, F.A.; SOUZA, M.A.; SILVA, D.A.O.; KASPER, L.H. & MINEO, J.R. - Detection of Toxoplasma gondii soluble antigen, SAG-1(p30), antibody and immune complex in
the cerebrospinal fluid of HIV positive or negative individuals. Rev. Inst. Med. trop. S. Paulo, 41(6): 329-338, 1999.

ACKNOWLEDGMENTS
The authors thank Dr. Mário E. Camargo and Kenneth Ely for their
careful review of this manuscript, Dr. Imtiaz A. Khan for providing us
6A 8 mAb and Dr. Monica Camargo Sopelete for her assistance in the
statistical analysis. This project was financially supported by FAPEMIG
and CNPq.
REFERENCES
1. ACEBS, M.V.; DIEZ, B.; GARCIA-RODRIGUES, J.A.; VIENS, P. & CISTERNA, R. Detection of circulating antigens in the diagnosis of acute toxoplasmosis. Amer. J.
trop. Med. Hyg., 51: 506-511, 1994.
2. ARAUJO, F.G. & REMINGTON, J.S. - Antigenemia in recently acquired acute
toxoplasmosis. J. infect. Dis., 141: 144-150, 1980.
3. BESSIÈRES, M.H.; LE BRETON, S. & SÉGUÉLA, J.P. - Analysis by immunoblotting
of Toxoplasma gondii exo-antigens and comparison with somatic antigens. Parasit.
Res., 78: 222-228, 1992.
4. BROOKS, R.G.; SHARMA, S.D. & REMINGTON, J.S. - Detection of Toxoplasma
gondii antigens by a dot-immunobinding technique. J. clin. Microbiol., 21: 113116, 1985.
5. CAMARGO, M.C.V.; ANTUNES, C.M.F. & CHIARI, C.A. – Epidemiologia da infecção
por Toxoplasma gondii no município de Ribeirão das Neves, MG. I. Importância dos
animais domésticos como fonte de infecção do T. gondii para o homem. Rev. Soc.
bras. Med. trop., 28: 211-214, 1995.
6. CAMARGO, M.E.; FERREIRA, A.W.; MINEO, J.R.; TAKIGUTI, C.K. & NAKAHARA,
O. S. - Immunoglobulin G and Immunoglobulin M enzyme-linked immunosorbent
assays and defined toxoplasmosis serological patterns. Infect. Immun., 21: 55-58,
1978.

16. HAFID, J.; TRAN-MANH-SUNG, R.; RABERIN, H. et al. - Detection of circulating
antigens of Toxoplasma gondii in human infection. Amer. J. trop. Med. Hyg., 52:
336-339, 1995.
17. HARLOW, E. & LANE, D. - Antibodies. New York, Cold Spring Harbor Laboratory,
1988.
18. HEDMAN, K.; LAPPALAINEN, M.; SEPPÄIÄ, I. & MÄKELÄ, O. - Recent primary
toxoplasma infection indicated by a low avidity of specific IgG. J. infect. Dis., 159:
736-740, 1989.
19. HELLERBRAND, C.; GOEBEL, E.D. & DISKO, R. - High predictive value of
Toxoplasma gondii IgG antibody levels in HIV-infected patients for diagnosis of
cerebral toxoplasmosis. Europ. J. clin. Microbiol. infect. Dis., 15: 869-872, 1996.
20. HERMENTIN, K.; HASSL, A.; PICHER, O. & ASPÖCK, H. - Comparison of different
serotests for specific Toxoplasma IgM-antibodies (ISAGA, SPIHA, IFAT) and
detection of circulating antigen in two cases of laboratory acquired Toxoplasma
infection. Zbl. Bakt. Mikrobiol. Hyg., 270: 534-541, 1989.
21. HOLLIMAN, R.E. - Toxoplasmosis and the acquired immune deficiency syndrome. J.
Infect., 16: 121-128, 1988.
22. HUNTER, C.A.; SUBAUSTE, C.S.; VAN CLEAVE, V.H. & REMINGTON, J.S. Production of gamma interferon by natural killer cells from Toxoplasma gondii infected SCID mice: regulation by interleukin-10, interleukin-12, and tumor necrosis
factor alpha. Infect. Immun., 62: 2818-2824, 1994.
23. KASPER, L.H.; CRABB, J.H. & PFEFFERKORN, E.R. - Purification of a major
membrane protein of T. gondii by immunoabsorption with a monoclonal antibody.
J. Immunol., 130: 2407-2412, 1983.
24. KHALIFA, K.E.S.; ROTH, A.; ROTH, B.; ARASTEH, K.N. & JANITSCHKE, K. Value of PCR for evaluating occurrence of parasitemia in immunocompromised
patients with cerebral and extracerebral toxoplasmosis. J. clin. Microbiol., 32: 28132819, 1994.

7. CESBRON-DELAUW, M.F. & CAPRON, A. - Excreted/secreted antigens of Toxoplasma
gondii: their origin and role in the host-parasite interaction. Res. Immunol., 144:
41-42, 1993.

25. LAEMLY, U.K. - Cleavage of structural proteins during the assembly of the head of
bacteriophage T4. Nature (Lond.), 227: 680-685, 1970.

8. CONTINI, C.; ROMANI, R.; MAGNO, S. & DELIA, S. - Diagnosis of Toxoplasma
gondii infection in AIDS patients by a tissue-culture technique Europ. J. clin.
Microbiol. infect. Dis., 14: 434-440, 1995.

26. LEBECH, M.; LEBECH, A.M.; NELSING, S.; VUUST, J.; MATHIESEN, L. &
PETERSEN, E. - Detection of Toxoplasma gondii DNA by polymerase chain reaction
in cerebrospinal fluid from AIDS patients with cerebral toxoplasmosis. J. infect.
Dis., 165: 982-983, 1992.

9. DUPOUY-CAMET, J.; SOUZA, S.L.; MASLO, C. et al. - Detection of Toxoplasma
gondii in venous blood from AIDS patients by polymerase chain reaction. J. clin.
Microbiol., 31: 1866-1869, 1993.
10. EGGERS, C.; GROB, U.; KLINKER, H. et al. - Limited value of cerebrospinal fluid for
direct detection of Toxoplasma gondii in toxoplasmic encephalitis associated with
AIDS. J. Neurol., 242: 644-649, 1995.
11. FALANGOLA, M.F. & PETITO, C.K. - Choroid plexus infection in cerebral
toxoplasmosis in AIDS patients. Neurology, 43: 2035-2040, 1993.

27. LETILLOIS, M.F.; LAIGLE ,V.; SANTORO, S.; MICOUD, M. & CHUMPOTAZI, B.F.
- Toxoplasma gondii surface antigen SAG-1 in sera of HIV-infected patients as an
indicator of reactivated toxoplasmosis. Europ. J. clin. Microbiol. infect. Dis., 14:
899-903, 1995.
28. LOWRY, O.H.; ROSEBROUGH, N.J.; FARR, A.L. & RANDALL, R.J. - Protein
measurement with the folin phenol reagent. J. biol. Chem., 193: 265-275, 1951.
29. LUFT, B.J. & REMINGTON, J.S. - AIDS commentary: toxoplasmic encephalitis. J.
infect. Dis., 157: 1-6, 1988.

12. FLECK, D.G. - Annotation: diagnosis of Toxoplasmosis. J. clin. Path., 42: 191-193, 1989.
13. FRIEDMAN, R.D. - Comparison of four different silver-staining techniques for salivary
protein detection in alkaline polyacrilamyde gels. Ann. Biochem., 126: 346-349,
1982.

30. MINEO, J.R.; CAMARGO, M.E. & FERREIRA, A.W. - Enzyme-linked immunosorbent
assay for antibodies to Toxoplasma gondii polysaccharides in human toxoplasmosis.
Infect. Immun., 27: 283-287, 1980.

14. GRINWOOD, J. & SMITH, J.E. - Toxoplasma gondii: the role of a 30-kDa surface
protein in host cell invasion. Exp. Parasit., 74: 106-111, 1992.

31. MINEO, J.R.; MCLEOD, R.; MACK , D. et al. - Antibodies to Toxoplasma gondii major
surface protein (SAG-1, P30) inhibit infection of host cells and are produced in murine
intestine after peroral infection. J. Immunol., 150: 3951-3964, 1993.

15. GROSS, U.; ROGGENKAMP, A.; JANITSCHKE, K. & HEESEMANN, J. - Improved
sensitivity of the polymerase chain reaction for detection of Toxoplasma gondii in
biological and human clinical specimens. Europ. J. clin. Microbiol. infect. Dis.,
11: 33-39, 1992.

32. NARITA, M.; YAMADA, S.; MATSUZONO, Y. et al. - Immunoglobin G avidity testing
in serum and cerebrospinal fluid for analysis of measles virus infections. Clin. Diag.
Lab. Immunol., 3: 211-215, 1996.

337

CHAVES-BORGES, F.A.; SOUZA, M.A.; SILVA, D.A.O.; KASPER, L.H. & MINEO, J.R. - Detection of Toxoplasma gondii soluble antigen, SAG-1(p30), antibody and immune complex in
the cerebrospinal fluid of HIV positive or negative individuals. Rev. Inst. Med. trop. S. Paulo, 41(6): 329-338, 1999.

33. POTASMAN, I.; ARAÚJO, F.G.; DESMONTS, G. & REMINGTON, J.S. - Analysis of
Toxoplasma gondii antigens recognized by human sera obtained before and after
acute infection. J. infect. Dis., 154: 650-657, 1986.

38. VELGE-ROUSSEL, F.; CHARDÈS, T.; MÉVÉLEC, P. et al - Epitopic analysis of the
Toxoplasma gondii major surface antigen SAG-1. Molec. Biochem. Parasit., 66:
31-38, 1994.

34. POTASMAN, I.; RESNICK, L.; LUFT, B.J. & REMINGTON, J.S. - Intrathecal production
of antibodies against Toxoplasma gondii in patients with toxoplasmic encephalitis
and the acquired immunodeficiency syndrome (AIDS). Ann. intern. Med., 108: 4951, 1988.

39. VINHAL, F.A.; PENA, J.D.O.; KATINA, J.H. et al. - Analysis of aqueous humor in
ocular toxoplasmosis: detection of low avidity IgG specific to Toxoplasma gondii.
Appl. Parasit., 35: 1-7, 1994.

35. RAHMAH, N. & KHAIRUL, A.A. - Comparison of three forms of antigens in the
demonstration of cell-mediated immune response in murine toxoplasmosis. Biochem.
biophys. Res. Commun., 189: 640-644, 1992.
36. ROWLAND, L.P.; FINK, M.E. & RUBIN, L. - Cerebrospinal fluid: blood-brain barrier,
brain edema, and hydrocephalus. In: KANDEL, E.R.; SCHWARTZ, J.H. & JESSELL,
T.M., ed. Principles of neural Science. 3. ed. New York, Elsevier Science, 1991. p.
1050-1060.
37. VAN KNAPEN, F. & PANGGABEAN, S.O. - Detection of circulating antigen during
acute infection with Toxoplasma gondii by enzyme-linked immunosorbent assay. J.
clin. Microbiol., 6: 545-547, 1977.

338

40. WAINSTEIN, M.V.; WOLFFENBUTTEL, L.; LOPES, D.K. et al. - Sensibilidade e
especificidade do diagnóstico clínico, sorológico e tomográfico da encefalite por
Toxoplasma gondii na síndrome da imunodeficiência adquirida (SIDA). Rev. Soc.
bras. Med. trop., 26: 571-575, 1988.
41. WEISS, L.M.; UDEM, S.A.; TANOWITZ, H. & WITTNER, M. - Western blot analysis
of the antibody response of patients with AIDS and Toxoplasma encephalitis: antigenic
diversity among Toxoplasma strains. J. infect. Dis., 157: 7-13, 1988.

Received: 18 June 1999
Accepted: 05 November 1999

